Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.88 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.74 |
| ▸ | HRH1 | P35367 | 5/20 | 0.63 |
| ▸ | HRH2 | P25021 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9228886 | 0.98 | HRH3 (0.85) | HRH3HRH4HRH1HRH2 | |
| SCHEMBL19182601 | 0.98 | HRH3 (0.85) | HRH3HRH4HRH1HRH2 | |
| SCHEMBL6909231 | 0.98 | HRH3 (0.85) | HRH3HRH4HRH1HRH2 | |
| SCHEMBL12138199 | 0.98 | HRH3 (0.85) | HRH3HRH4HRH1HRH2 | |
| SCHEMBL7576395 | 0.98 | HRH3 (0.85) | HRH3HRH4HRH1HRH2 | |
| SCHEMBL1031431 | 0.94 | — | — | |
| SCHEMBL8964986 | 0.89 | HRH3 (0.79) | HRH3HRH4HRH1HRH2 | |
| SCHEMBL8963957 | 0.87 | HRH3 (0.80) | HRH3HRH4HRH1HRH2 | |
| SCHEMBL4186577 | 0.87 | HRH3 (0.67) | HRH3HRH4HRH1 | |
| SCHEMBL8963886 | 0.84 | HRH3 (0.75) | HRH3HRH4HRH1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110575-A1 | OLIGOMERISATION OF ALCOHOLS | Terra Mater BV (BE) | 2024-05-30 | — | — | WO | claimed |
| WO-2024110575-A1 | OLIGOMERISATION OF ALCOHOLS | Terra Mater BV (BE) | 2024-05-30 | — | — | WO | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8912341-B2 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NORTHWESTERN UNIVERSITY (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140206886-A1 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NORTHWESTERN UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2013151450-A1 | AROMATIC IMIDAZOLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES OF BACTERIAL NATURE | Uniwersytet Jagielloński (PL) | 2013-10-10 | — | — | WO | disclosed |
| EP-1927590-B1 | METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2011-07-20 | — | — | EP | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| WO-2002085863-A1 | NOVEL COMPOUNDS OF THE FAMILY OF 3-ALKYL-(4,5 DIPHENYL-IMIDAZOL-1-YL) AND THEIR USE AS SOOTHING AGENTS | L'OREAL (FR) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085864-A1 | COMPOUNDS OF THE FAMILY OF 3-ALKYL-(4,5 DIPHENY-IMIDAZOL-1-YL) AND THEIR USE AS SOOTHING AGENTS | L'OREAL (FR) | 2002-10-31 | — | — | WO | disclosed |
| US-5824696-A | ANGIOTENSIN II RECEPTOR ANTAGONIST AS ANTIINFLAMMATORY AGENTS USING HETEROCYCLIC ACID COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-20 | — | — | US | disclosed |
| EP-0724387-A4 | TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES BY ANGIOTENSION II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0724387-A1 | TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES BY ANGIOTENSION II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-07 | — | — | EP | disclosed |
| CN-1112364-A | Piperazine derivatives and salts thereof | OTSUKA PHARMA CO LTD (JP) | 1995-11-22 | — | — | CN | disclosed |
| WO-1995006410-A1 | TREATMENT OF CHRONIC INFLAMMATORY DISEASES BY ANGIOTENSION II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-09 | — | — | WO | disclosed |
| EP-0559755-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0559755-A1 | SUBSTITUTED 5-ARYL IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009278-A1 | SUBSTITUTED 5-ARYL IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206886-A1 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NISCH, NIM1K, CDK18 | HRH3 3113/4885HRH4 1223/4885HRH1 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.